Description
Book SynopsisPractising evidence-based medicine necessarily depends on the clinician having access to the best evidence available, but in a fast-moving field, keeping up to date with the latest developments is a challenging prospect. In this new volume, leading experts focus on the most important clinical issues associated with the management of Lipid Disorders, evaluating and interpreting the evidence available to provide the reader with a reliable summary of our current knowledge. Topics covered include therapeutic strategies for managing hereditary lipid disorders, including familial hypercholesterolaemia, both in adults and children, and familial combined hypercholesterolaemia. The authors also evaluate the evidence for a link between inflammatory disease and cardiovascular risk; the metabolic syndrome and the interconnections between dyslipidaemias and diabetes. They also look at therapeutic challenges such as the management of patients who are statin resistant, and the control of lipid levels in those suffering renal insufficiency. Tables highlight important data, evidence from trial results and expert reports, and each section concludes with a series of Key Points that present a summary of evidence-based recommendations for best practice, graded according to the quality of that evidence. The book provides the busy clinician with a unique analysis of the data supporting current therapies and will help the reader formulate effective strategies for treating their own patients.
Table of ContentsLipoprotein metabolism: what do we know now?; The epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases; Are lifestyle modifications a successful means for controlling lipid levels in the long run?; What are the diagnostic and therapeutic strategies for hereditary hypo-and hypercholesterolaemia?; Does raising HDL protect against atherosclerosis?; How do we diagnose hypertriglyceridaemia in clinical practice and what are the consequences for treatment?; What is the optimal treatment of familial combined hypercholesterolaemia?; How should we manage lipid and lipoprotein disorders in children?; What is the role of dyslipidaemia in the metabolic syndrome and diabetes mellitus?; What are the consequences of renal insufficiency or the nephrotic syndrome for lipid levels?; Is there a link between chronic inflammatory diseases and cardiovascular risk?; What is the evidence for a physiological and pathogenic role of lipoprotein (a)?; How do we identify and treat sitosterolaemia?; How can we deal with inborn errors in cholesterol and bile acid biosynthesis?; Differential diagnosis of patients with tendon xanthomas; When should we fear for statin interactions?; What are the considerations in patients who are statin resistant?
